A Hybrid Computational Intelligence Framework with Metaheuristic Optimization for Drug-Drug Interaction Prediction

• URL: http://arxiv.org/abs/2510.09668v1
• Date: Wed, 08 Oct 2025 09:55:18 GMT
• Title: A Hybrid Computational Intelligence Framework with Metaheuristic Optimization for Drug-Drug Interaction Prediction
• Authors: Maryam Abdollahi Shamami, Babak Teimourpour, Farshad Sharifi,
• Abstract summary: Drug-drug interactions (DDIs) are a leading cause of preventable adverse events, often complicating treatment and increasing healthcare costs.<n>We propose an interpretable and efficient framework that blends modern machine learning with domain knowledge to improve DDI prediction.<n>Our approach combines two complementary embeddings - Mol2Vec, which captures fragment-level structural patterns, and SMILES-BERT, which learns contextual chemical features.
• Score: 0.8602553195689512
• License: http://creativecommons.org/publicdomain/zero/1.0/
• Abstract: Drug-drug interactions (DDIs) are a leading cause of preventable adverse events, often complicating treatment and increasing healthcare costs. At the same time, knowing which drugs do not interact is equally important, as such knowledge supports safer prescriptions and better patient outcomes. In this study, we propose an interpretable and efficient framework that blends modern machine learning with domain knowledge to improve DDI prediction. Our approach combines two complementary molecular embeddings - Mol2Vec, which captures fragment-level structural patterns, and SMILES-BERT, which learns contextual chemical features - together with a leakage-free, rule-based clinical score (RBScore) that injects pharmacological knowledge without relying on interaction labels. A lightweight neural classifier is then optimized using a novel three-stage metaheuristic strategy (RSmpl-ACO-PSO), which balances global exploration and local refinement for stable performance. Experiments on real-world datasets demonstrate that the model achieves high predictive accuracy (ROC-AUC 0.911, PR-AUC 0.867 on DrugBank) and generalizes well to a clinically relevant Type 2 Diabetes Mellitus cohort. Beyond raw performance, studies show how embedding fusion, RBScore, and the optimizer each contribute to precision and robustness. Together, these results highlight a practical pathway for building reliable, interpretable, and computationally efficient models that can support safer drug therapies and clinical decision-making.

Related papers

• Dual-Pathway Fusion of EHRs and Knowledge Graphs for Predicting Unseen Drug-Drug Interactions [5.481037938702276]
  Drug-drug interactions (DDIs) remain a major source of preventable harm.<n>We introduce, to our knowledge, the first system that conditions KG relation scoring on patient-level EHR context.<n>A fusion "Teacher" learns mechanism-specific relations for drug pairs represented in both sources.<n>A distilled "Student" generalizes to new or rarely used drugs without KG access at inference.
  arXiv  Detail & Related papers  (2025-11-10T03:18:16Z)
• Retrieval Augmented Large Language Model System for Comprehensive Drug Contraindications [0.0]
  The versatility of large language models (LLMs) has been explored across various sectors, but their application in healthcare poses challenges.<n>This study enhances the capability of LLMs to address contraindications effectively by implementing a Retrieval Augmented Generation (RAG) pipeline.
  arXiv  Detail & Related papers  (2025-08-08T09:09:03Z)
• DPASyn: Mechanism-Aware Drug Synergy Prediction via Dual Attention and Precision-Aware Quantization [2.8158058913878268]
  Drug combinations are essential in cancer therapy, leveraging synergistic drug-drug interactions (DDI) to enhance efficacy and combat resistance.<n>We propose DPASyn, a novel drug synergy prediction framework featuring a dual-attention mechanism and Precision-Aware Quantization (PAQ)<n>The dual-attention architecture jointly models intra-drug structures and inter-drug interactions via shared projections and cross-drug attention, enabling fine-grained, biologically plausible synergy modeling.
  arXiv  Detail & Related papers  (2025-05-25T13:40:13Z)
• Multimodal AI predicts clinical outcomes of drug combinations from preclinical data [38.31103891121078]
  We introduce Madrigal, a multimodal AI model that learns from structural, pathway, cell viability, and transcriptomic data to predict drug-combination effects.<n>Madrigal uses an attention bottleneck module to unify preclinical drug data modalities.<n>It outperforms single-modality methods and state-of-the-art models in predicting adverse drug interactions.
  arXiv  Detail & Related papers  (2025-03-04T16:55:14Z)
• KITE-DDI: A Knowledge graph Integrated Transformer Model for accurately predicting Drug-Drug Interaction Events from Drug SMILES and Biomedical Knowledge Graph [0.11049608786515838]
  Drug-Drug Interactions (DDI) can cause significant bodily injury and even death.<n>Most contemporary research for predicting DDI events relies on either information from Biomedical Knowledge graphs (KG) or drug SMILES.<n>In this study, we propose a KG-integrated Transformer architecture to generate an end-to-end fully automated Machine Learning pipeline.
  arXiv  Detail & Related papers  (2024-12-08T00:49:57Z)
• A Cross-Field Fusion Strategy for Drug-Target Interaction Prediction [85.2792480737546]
  Existing methods fail to utilize global protein information during DTI prediction. Cross-field information fusion strategy is employed to acquire local and global protein information. Siamese drug-target interaction SiamDTI prediction method achieves higher accuracy levels than other state-of-the-art (SOTA) methods on novel drugs and targets.
  arXiv  Detail & Related papers  (2024-05-23T13:25:20Z)
• drGT: Attention-Guided Gene Assessment of Drug Response Utilizing a Drug-Cell-Gene Heterogeneous Network [8.664433151000255]
  drGT is a graph deep learning model that predicts sensitivity and aids in biomarker identification using attention coefficients (ACs)<n>The model is trained and evaluated using major benchmark datasets: Sanger GDSC, NCI60, and Broad CTRP, which cover a wide range of drugs and cancer cell lines.
  arXiv  Detail & Related papers  (2024-05-14T22:16:52Z)
• Physical formula enhanced multi-task learning for pharmacokinetics prediction [54.13787789006417]
  A major challenge for AI-driven drug discovery is the scarcity of high-quality data. We develop a formula enhanced mul-ti-task learning (PEMAL) method that predicts four key parameters of pharmacokinetics simultaneously. Our experiments reveal that PEMAL significantly lowers the data demand, compared to typical Graph Neural Networks.
  arXiv  Detail & Related papers  (2024-04-16T07:42:55Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• SSM-DTA: Breaking the Barriers of Data Scarcity in Drug-Target Affinity Prediction [127.43571146741984]
  Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery. wet experiments remain the most reliable method, but they are time-consuming and resource-intensive. Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue. We present the SSM-DTA framework, which incorporates three simple yet highly effective strategies.
  arXiv  Detail & Related papers  (2022-06-20T14:53:25Z)
• HINT: Hierarchical Interaction Network for Trial Outcome Prediction Leveraging Web Data [56.53715632642495]
  Clinical trials face uncertain outcomes due to issues with efficacy, safety, or problems with patient recruitment. In this paper, we propose Hierarchical INteraction Network (HINT) for more general, clinical trial outcome predictions.
  arXiv  Detail & Related papers  (2021-02-08T15:09:07Z)
• Discovering Synergistic Drug Combinations for COVID with Biological Bottleneck Models [38.637412590671865]
  We propose a emphbiological bottleneck model that jointly learns drug-target interaction and synergy. The model consists of two parts: a drug-target interaction and target-disease association module. We experimentally tested the model predictions in the U.S. National Center for Advancing Translational Sciences.
  arXiv  Detail & Related papers  (2020-11-09T03:30:44Z)
• Deep Learning for Virtual Screening: Five Reasons to Use ROC Cost Functions [80.12620331438052]
  deep learning has become an important tool for rapid screening of billions of molecules in silico for potential hits containing desired chemical features. Despite its importance, substantial challenges persist in training these models, such as severe class imbalance, high decision thresholds, and lack of ground truth labels in some datasets. We argue in favor of directly optimizing the receiver operating characteristic (ROC) in such cases, due to its robustness to class imbalance.
  arXiv  Detail & Related papers  (2020-06-25T08:46:37Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.